Wajgt A, Szyrocka-Szwed K, Gadomska B, Szczechowski L
I Katedry i Kliniki Neurologii Sl. AM w Katowicach.
Neurol Neurochir Pol. 1988 Nov-Dec;22(6):518-23.
Cyclophosphamide (4000 mg intravenously, in daily doses of 400 mg) in combination with moderate dose of prednisone (1075 mg during 30 days) was given to 39 patients with the chronically progressing form of multiple sclerosis. The results of this treatment were evaluated immediately after the treatment and one and two years later, using a numerical scale of neurological examination in the scales of motor efficiency A. I. (ambulation index) and the DDS (disability status scale of Kurtzke). In the first year after this treatment stabilization of the disease (60% of cases) or even clinical improvement (10-20%) were noted. However, in the second year after the treatment an evident progression of symptoms occurred in 50-60% of cases. In view of moderately positive results of this treatment it is necessary to carry out observations extended over many years, to repeat cyclophosphamide cycles, and to compare the results with those after other immunosuppressants.
对39例慢性进行性多发性硬化症患者给予环磷酰胺（静脉注射4000毫克，每日剂量400毫克）联合中等剂量泼尼松（30天内1075毫克）治疗。治疗结束后立即以及1年和2年后，使用运动效率A.I.（步行指数）和DDS（库茨克残疾状态量表）的神经学检查数字量表评估该治疗的结果。在该治疗后的第一年，观察到疾病稳定（60%的病例）甚至临床改善（10 - 20%）。然而，在治疗后的第二年，50 - 60%的病例出现症状明显进展。鉴于该治疗的适度阳性结果，有必要进行多年的观察，重复环磷酰胺疗程，并将结果与其他免疫抑制剂治疗后的结果进行比较。
